cyproheptadine (periactin) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Glutodine (Cyproheptadine), sold under the brand name Periactin or Peritol, is a first-generation antihistamine with additional antiserotonergic, anticholinergic and local anesthetic properties. Glutodine is a white to slightly yellowish crystalline solid, which is soluble in water, freely soluble in methanol, sparingly soluble in ethanol, soluble in chloroform, and practically insoluble in ether. Cyproheptadine is used to treat allergic reactions (specifically hay fever), Vasomotor rhinitis, Allergic conjunctivitis due to inhalant allergens and foods, uncomplicated allergic skin manifestations of urticaria and angioedema amelioration of allergic reactions to blood or plasma, Cold urticaria, and Dermatographism. Cyproheptadine is used off-label to treat Spasticity Associated With Spinal Cord, Migraine Headache Prophylaxis, Decreased Appetite Secondary to Chronic Disease, Drug-Induced Sexual Dysfunction, Serotonin Syndrome.   NCATS

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$0.0445 - $0.5597
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

1-methyl-4-(5-dibenzo(a,e)cycloheptatrienylidene)piperidine | 1-methyl-4-(5h-dibenzo(a,d)cycloheptenylidene)piperidine | 4-(5-dibenzo(a,d)cyclohepten-5-ylidine)-1-methylpiperidine | 4-(5h-dibenzo(a,d)cyclohepten-5-ylidene)-1-methylpiperidine | 4-dibenzo[a,d]cyclohepten-5-ylidene-1-methyl-piperidine | 5-(1-methylpiperidylidene-4)-5h-dibenzo(a,d)cyclopheptene | axoprol | ciproheptadina | cycloheptadine | cyproheptadin | cyproheptadine | cyproheptadine hcl | cyproheptadine hydrochloride | cyproheptadine hydrocloride | cyproheptadinum | dihexazin | glutodina | periactin | periactinol

Organizations (74)

Research & Development (32)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (42)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (34)

Approved Indications (10)


 

Anaphylaxis (approved 1980)

Angioedema (approved 1980)

Conjunctivitis, Allergic (approved 1980)

Migraine Disorders

Pruritus

Rhinitis, Allergic, Perennial (approved 1980)

Rhinitis, Allergic, Seasonal (approved 1980)

Rhinitis, Vasomotor (approved 1961)

Schizophrenia

Urticaria (approved 1980)

Experimental Indications - Clinical Trial Phases 1-4 (24)


 

Abdominal Pain (Phase 2)

Alcoholism (Phase 2)

Attention Deficit and Disruptive Behavior Disorders (Phase 4)

Attention Deficit Disorder with Hyperactivity (Phase 4)

Blood Platelet Disorders (Phase 3)

Brain Neoplasms (Phase 2)

Cachexia (Phase 2)

Central Nervous System Neoplasms (Phase 2)

Child Nutrition Disorders (Phase 2/Phase 3)

COVID-19 (Phase 3)

Failure to Thrive (Phase 4)

Feeding Behavior (Phase 4)

Leukemia (Phase 2)

Lymphoma (Phase 2/Phase 3)

Mitral Valve (Phase 2)

Muscle Hypotonia (Phase 2/Phase 3)

Myelodysplastic-Myeloproliferative Diseases (Phase 2)

Myelodysplastic Syndromes (Phase 2)

Neoplasms (Phase 3)

Neurodevelopmental Disorders (Phase 4)

Pneumonia, Viral (Phase 3)

Serotonin Syndrome (Phase 3)

Stroke (Early Phase 1)

Treatment Outcome (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 19
  • # of Trial Organizations: 32

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue